About Sickle Cell Disease

Sickle cell disease is one of the most common genetic conditions in the world and was the “first molecular disease.” The clinical phenotype is very variable, with many patients developing chronic organ damage involving the lungs, heart, brain, eye, liver and kidneys in childhood or young adulthood, as well as suffering acute painful and chest crises and chronic pain, while others stay relatively healthy into middle and old age. Genetic, environmental, animal, and clinical studies have discovered new mechanisms, biomarkers, and therapeutic targets for sickle cell disease.

This collection aims to publish content relating to clinical phenotype and therapies, novel biomarkers, environmental exposures, pathophysiological mechanisms, and new potential targets for future therapies.

F1000 Research welcomes submissions of a wide range of article types, including but not limited to research articles, case reports, method articles, reviews, and opinion articles.  Each article will undergo fully transparent post-publication peer review following the F1000Research publication model. 

We warmly encourage members of all disciplines involved in the clinical and research sickle cell disease communities to share their work here.

Keywords: sickle cell anemia, hemoglobin SC disease, hemoglobin S-β thalassemia, hemoglobin F, pain, pulmonary hypertension, stroke, seizures, retinopathy, leg ulcers, chronic renal failure, priapism, pregnancy

Any questions about this collection? Please get in contact directly with research@f1000.com.